Welcome to the April installment of Multiple Myeloma Updates for Advanced Practitioners in Oncology.
This month, JNCCN—Journal of the National Comprehensive Cancer Network, which is published by Harborside Press (the publisher of JADPRO), focuses its Guidelines Insights feature on the recent changes to the NCCN Clinical Practice Guidelines in multiple myeloma. It’s only April, and we already have version 3.2016 as the most recent guideline, with additional revisions in process! These numerous updates—including changes to the diagnosis and management of myeloma as well as to the art of treatment and monitoring—reflect the rapidly changing landscape of this disease.
I’ve selected some interesting articles about MM in the news and in the literature to add to this growing resource, which I hope you find to be a valuable collection of information.
In this month's newsletter, our video roundtable focuses on treatment selection and risk stratification for patients with MM. This portion of our roundtable includes important information about the influential SWOG 0777 trial. At just under three and a half minutes, it is well worth your valuable time.
As always, feel free to share this MM resource, the video roundtable discussion, and the JADPRO supplement with your colleagues.
Beth Faiman, PhD, APN-BC, AOCN
Multiple Myeloma Program
Taussig Cancer Institute